Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 18/20 | 0.54 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | FPR1 | P21462 | 1/20 | 0.53 |
| ▸ | TACR3 | P29371 | 1/20 | 0.53 |
| ▸ | GPR183 | P32249 | 1/20 | 0.53 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.53 |
| ▸ | GPR65 | Q8IYL9 | 1/20 | 0.53 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28415289 | 1.00 | TACR1 (0.54) | TACR1NR3C1CYP3A4FPR1TACR3 | |
| SCHEMBL28409436 | 1.00 | TACR1 (0.54) | TACR1NR3C1CYP3A4FPR1TACR3 | |
| SCHEMBL264332 | 1.00 | TACR1 (0.54) | TACR1NR3C1CYP3A4FPR1TACR3 | |
| SCHEMBL5222535 | 1.00 | TACR1 (0.54) | TACR1NR3C1CYP3A4FPR1TACR3 | |
| SCHEMBL271095 | 1.00 | TACR1 (0.54) | TACR1NR3C1CYP3A4FPR1TACR3 | |
| SCHEMBL14900670 | 1.00 | TACR1 (0.54) | TACR1NR3C1CYP3A4FPR1TACR3 | |
| SCHEMBL271421 | 1.00 | TACR1 (0.54) | TACR1NR3C1CYP3A4FPR1TACR3 | |
| SCHEMBL5220886 | 1.00 | TACR1 (0.54) | TACR1NR3C1CYP3A4FPR1TACR3 | |
| SCHEMBL12991595 | 1.00 | TACR1 (0.54) | TACR1NR3C1CYP3A4FPR1TACR3 | |
| SCHEMBL5222778 | 1.00 | TACR1 (0.54) | TACR1NR3C1CYP3A4FPR1TACR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2817305-B1 | AN IMPROVED PROCESS FOR THE PREPARATION OF APREPITANT | PIRAMAL ENTPR LTD (IN) | 2016-09-28 | — | — | EP | claimed |
| JP-4647783-B2 | — | — | 2011-03-09 | — | — | JP | claimed |
| US-20030187274-A1 | Process for the preparation of 1,2,4- triazolin-5-one derivatives | MERCK SHARP & DOHME LTD. (GB) | 2003-10-02 | — | — | US | claimed |
| JP-2002518388-A | — | — | 2002-06-25 | — | — | JP | claimed |
| EP-1087966-B1 | CHEMICAL SYNTHESIS OF MORPHOLINE DERIVATIVES | MERCK SHARP & DOHME (GB) | 2002-05-08 | — | — | EP | claimed |
| US-20020019524-A1 | Chemical synthesis of morpholine derivatives | MERCK SHARP & DOHME LIMITED | 2002-02-14 | — | — | US | claimed |
| US-6297376-B1 | POTENT AND SELECTIVE SUBSTANCE P (OR NEUROKININ-1) RECEPTOR ANTAGONISTS. ONE-STEP ALKYLATION WITH 3-CHLOROMETHYL-1,2,4-TRIAZOLIN-5-ONE, | MERCK SHARP & DOHME LTD. (GB) | 2001-10-02 | — | — | US | claimed |
| EP-1124826-A1 | PROCESS FOR THE PREPARATION OF 2-(R)-(1- (R)-(3,5-BIS (TRIFLUOROMETHYL) PHENYL)ETHOXY) -4-((5-DIMETHYLAMINOMETHYL) -1,2,3-TRIAZOL -4-YL)METHYL) -3-(S)-(4- FLUOROPHENYL) MORPHOLINE | Merck & Co., Inc. (US) | 2001-08-22 | — | — | EP | claimed |
| EP-1087966-A1 | CHEMICAL SYNTHESIS OF MORPHOLINE DERIVATIVES | MERCK SHARP & DOHME LTD. (GB) | 2001-04-04 | — | — | EP | claimed |
| WO-2000026215-A1 | PROCESS FOR THE PREPARATION OF 2-(R)-(1- (R)-(3,5-BIS (TRIFLUOROMETHYL) PHENYL)ETHOXY) -4-((5-DIMETHYLAMINOMETHYL) -1,2,3-TRIAZOL -4-YL)METHYL) -3-(S)-(4- FLUOROPHENYL) MORPHOLINE | MERCK & CO., INC. (US) | 2000-05-11 | — | — | WO | claimed |
| WO-2000026214-A1 | LINEAR PROCESS FOR THE PREPARATION OF A MORPHOLINE COMPOUND | MERCK & CO., INC. (US) | 2000-05-11 | — | — | WO | claimed |
| US-6051707-A | FOR USE IN THE TREATMENT OF INFLAMMATORY DISEASES, EMESIS, DEPRESSSION, ANXIETY, AND OTHER NEUROPSYCHIATRIC DISEASES, INCLUDING BIPOLAR DISORDER AND SCHIZOPHRENIA; SUBSTANCE P (OR NEUROKININ-1) RECEPTOR ANTAGONIST | MERCK & CO., INC. (US) | 2000-04-18 | — | — | US | claimed |
| US-6051717-A | SUBSTANCE P RECEPTOR ANTAGONIST; POTENTIAL FOR USE IN THE TREATMENT OF INFLAMMATORY DISEASES, EMESIS, DEPRESSION, ANXIETY, AND OTHER NEUROPSYCHIATRIC DISEASES | MERCK & CO., INC. (US) | 2000-04-18 | — | — | US | claimed |
| WO-1999065900-A1 | CHEMICAL SYNTHESIS OF MORPHOLINE DERIVATIVES | MERCK SHARP & DOHME LIMITED (GB) | 1999-12-23 | — | — | WO | claimed |
| EP-2817305-B1 | AN IMPROVED PROCESS FOR THE PREPARATION OF APREPITANT | PIRAMAL ENTPR LTD (IN) | 2016-09-28 | — | — | EP | disclosed |
| US-20160031867-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF APREPITANT | Piramal Enterprises Limited (IN) | 2016-02-04 | — | — | US | disclosed |
| EP-2817305-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF APREPITANT | Piramal Enterprises Limited (IN) | 2014-12-31 | — | — | EP | disclosed |
| WO-1997018206-A1 | MORPHOLINE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | MERCK SHARP & DOHME LIMITED (GB) | 1997-05-22 | — | — | WO | disclosed |
| US-5610159-A | N-oxides of morpholine derivatives and their use as therapeutic agents | MERCK SHARP & DOHME LIMITED (GB) | 1997-03-11 | — | — | US | disclosed |
| WO-1996020009-A1 | USE OF A TACHYKININ ANTAGONIST AND AN OPIOID ANALGESIC | MERCK SHARP & DOHME LIMITED (GB) | 1996-07-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020019524-A1 | Chemical synthesis of morpholine derivatives | OPRM1, OPRK1, OPRL1 | TACR1 48/4885NR3C1 3111/4885CYP3A4 33/4885 |
| US-20030187274-A1 | Process for the preparation of 1,2,4- triazolin-5-one derivatives | CYP1B1, ADRA2C, CYP1A1 | TACR1 573/4885NR3C1 1698/4885CYP3A4 34/4885 |
| US-20160031867-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF APREPITANT | HRH1, HRH2, HRH3 | TACR1 100/4885NR3C1 562/4885CYP3A4 43/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.